ClinicalTrials.gg
Active, not recruitingNCT05360446V-PLAQUEUpdated Oct 26, 2026

Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events

A Phase 3 interventional study of Inclisiran sodium 300 mg and Placebo in Coronary Artery Disease, sponsored by Novartis Pharmaceuticals. Active, not recruiting at 89 sites in 18 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Updated Oct 26, 2026Study completion movedEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
610
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Coronary Artery Disease by Novartis — 1 open to participants now, 3 under way, 2 of them phase 3. Coronary Artery Disease · Novartis.

Enrollment
3rd of 10
610 · median 97
Started
2022
the only one that year
Phase 3
4 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Coronary Artery Disease by Novartis, this one is the 3rd largest by enrollment, is the only one that started in 2022, is one of 4 in phase 3, and was the 8th registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

1 of the 10 studies in Coronary Artery Disease by Novartis is open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Coronary Artery Disease by Novartis, or all of them as a file.
02

Study summary

CKJX839D12303 is a research study to determine if the study treatment, called inclisiran, in comparison to placebo taken in addition to statin medication can effectively reduce the total amount of plaque formed in the heart's vessels as measured by coronary computed tomography angiography (CCTA) from baseline to month 24. This study is being conducted in eligible participants with a diagnosis of non-obstructive coronary artery disease (NOCAD), where the coronary arteries are blocked less than 50%, and with no previous cardiovascular events.

Read the detailed description

The purpose of this study is to evaluate the efficacy of inclisiran compared to placebo on top of maximally tolerated dose of statin therapy in reducing total coronary atheroma volume assessed by CCTA in participants with a diagnosis of Non-Obstructive Coronary Artery Disease (NOCAD) without previous cardiovascular events, who have an LDL-C ≥55 mg/dL (1.4 mmol//L), no significant pressure drop in Fractional Flow Reserve Computed Tomography (FFRCT) and a CT-adapted Leaman score >5 despite the use of maximally tolerated statin therapy(and if applicable, another LLT on top of statin therapy for at least 30 days in up to 20% of randomized participants).

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Inclisiran
  • KJX839
  • Atherosclerotic plaques
  • CCTA
  • CT-adapted Leaman score
  • LDL-C
  • FFRct
  • NOCAD
  • PCSK9 inhibitor
  • TAV
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥18 years or ≤80 years of age at signing of .
  • Fasting LDL-C local lab value at the Screening Visit of either i) ≥100 mg/dL (2.6 mmol/L) if on statin therapy but not on a maximally tolerated statin therapy; ii) ≥150 mg/dL (3.9mmol/L) if statin naive and without documented statin intolerance; or iii) ≥55 mg/dL (1.4 mmol/L) if on a stable (≥4 weeks) dose of maximally tolerated statin therapy or if statin intolerant.
  • Fasting LDL-C local lab value ≥55 mg/dL (1.4 mmol/L) at the assessment performed during the Statin Optimization Period 3 Visit for participants going through the Statin Optimization Period.
  • Participants having NOCAD without previous cardiovascular events: NOCAD is defined as:.

    1. Participant with CT-adapted Leaman score >5. and a diameter stenosis \<50% or
    2. Participants with a CT-adapted Leaman score >5, a diameter stenosis ≥50% but with FFRCT ≥0.76.
  • A standard of care CCTA may serve as the study baseline CCTA scan if it is performed within 3 months prior to the participant's Screening Visit and meets the inclusion criteria of FFRct >0.8 and CT-adapted Leaman score >5, which will be assessed by the Imaging Core Lab.
  • At the Baseline Visit, participants must be on a stable (≥4 weeks) dose of maximally tolerated statin therapy. Participants not on maximally tolerated statin therapy and who do not have documented statin intolerance can be screened but must enter the study via a Statin Optimization Period.
  • Fasting LDL-C lab value ≥55 mg/dL (1.4 mmol/L) at the Baseline Visit, measured at the central laboratory. If the Baseline and Screening Visits occur on the same day, then the LDL-C assessment will be assessed on the central laboratory sample. If a participant qualifies at Screening but the fasting central lab LDL-C value at the Baseline visit does not meet eligibility, then eligibility will be determined based on the central lab result.
  • Fasting triglycerides value \<400 mg/dL (4.52 mmol/L) based on the local lab results at the Screening visit and on the central lab results at the CCTA visit.

Exclusion criteria

Exclusion Criteria:

  • Previous cardiovascular events history including myocardial infarction (MI), or prior coronary revascularization [percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG)].
  • Planned revascularization (PCI) or (CABG).
  • Previous cerebrovascular events including:

    • Prior ischemic stroke thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus.
    • History of prior percutaneous or surgical carotid artery revascularization.
  • History of Peripheral Artery Disease (PAD):

    • Prior documentation of a resting ankle-brachial index \<0.85.
    • History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery.
    • Prior non-traumatic amputation of a lower extremity due to peripheral artery disease.
  • Cardiac disorders, including any of the following:

    • cardiac arrhythmias (e.g., ventricular tachycardia, atrial fibrillation) within 3 months prior to randomization that is not controlled by medication or via ablation at the time of the Screening Visit.
    • Complete left bundle branch block, high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II and third-degree AV block) prior to randomization.
  • for CCTA (e.g., allergic reactions to the contrast dye) or CCTA not meeting entry standards after two attempts during the Baseline CCTA Visit as assessed by the Imaging Core Lab.
  • Pacemaker or implantable cardioverter-defibrillator (ICD) in situ.
  • Systolic Left Ventricle \<30% at the Screening Visit.
  • Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or diastolic blood pressure >110 mmHg prior to randomization (assessed at the Screening Visit) despite antihypertensive therapy.
  • Heart failure (NYHA) class III or class IV at the Screening Visit.
  • Renal insufficiency ( \<30 mL/min/1.73m2) as measured by the Modification of Diet in Renal Disease (MDRD) formula at the Screening Visit and at the Statin Optimization 3 Visit.
  • Active liver disease defined as any known current infectious, neoplastic, or metabolic pathology of the liver at the Screening Visit.
  • Local creatine kinase (CK) values of either, unless a more stringent threshold is mandated by a local regulatory authority
  • Local CK values ≥5x at the Statin Optimization 3 Visit unless a more stringent threshold is mandated by a local regulatory authority
  • Participant with myopathy at the Statin Optimization 3 Visit.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
610 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subcutaneous injection

    Drug: Placebo

  • Experimental
    Inclisiran sodium

    Subcutaneous injection

    Drug: Inclisiran sodium 300 mg

Interventions

  • Subcutaneously administered on Days 1, Month 3 (Day 90), and every 6 months thereafter.

  • DrugPlacebo

    Subcutaneously administered on Day 1, Month 3 (Day 90), and every 6 months thereafter.

06

What researchers measure

Primary outcomes

  1. Percentage change in total coronary atheroma volume

    Evaluating inclisiran compared to placebo both on top of maximally tolerated statin therapy in reducing total coronary atheroma volume assessed by coronary computed tomography angiography (CCTA) in participants with a diagnosis of non-obstructive coronary artery disease (NOCAD) without previous cardiovascular events.

    Time frame: From baseline to month 24

Secondary outcomes

  1. Percentage change in LDL-C

    Full fasting lipid panel will be collected throughout the study beginning at baseline.

    Time frame: From baseline to month 24

  2. Percentage change in low attenuation plaque volume evaluated by CCTA

    Evaluating inclisiran compared to placebo in percentage change in low attenuation plaque volume evaluated by CCTA.

    Time frame: From baseline to month 24

  3. Percentage of participants with progression, regression, or no change of total plaque atheroma volume

    Evaluating inclisiran compared to placebo in percentage of participants experiencing progression, regression, or no change of total atheroma volume.

    Time frame: From baseline to month 24

07

Study locations

89 sites
  • Heart Center Research Llc
    Huntsville, Alabama 35801, United States
  • Alaska Heart and Vascular
    Anchorage, Alaska 99508, United States
  • Cardiovascular Res Found
    Beverly Hills, California 90210, United States
  • UC San Diego Health
    La Jolla, California 92037, United States
  • Stanford Health Care
    Stanford, California 94305, United States
  • Lundquist Inst BioMed at Harbor
    Torrance, California 90509-2910, United States
  • Bridgeport Hospital
    Bridgeport, Connecticut 06610, United States
  • George Washington Univ Medical Ctr
    Washington D.C., District of Columbia 20037, United States
  • Inpatient Research Clinical LLC
    Miami Lakes, Florida 33014, United States
  • NorthShore University Health System
    Evanston, Illinois 60201, United States
  • Reid Physician Associates
    Richmond, Indiana 47374, United States
  • Midwest Heart and Vascular Spec
    Overland Park, Kansas 66211, United States
  • Anderson Medical Research
    Ft. Washington, Maryland 20744, United States
  • Minneapolis Heart Institute
    Minneapolis, Minnesota 55407, United States
  • R Ins For Heart And Vascular Health
    Reno, Nevada 89502, United States
  • Cardio Metabolic Institute
    Somerset, New Jersey 08873, United States
  • Icahn School of Med at Mt Sinai
    New York, New York 10029, United States
  • State Uni of NY at Stony Brook
    Stony Brook, New York 11794-3362, United States
  • Westchester Medical Center
    Valhalla, New York 10595, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Oregon Health Sciences University
    Portland, Oregon 97239, United States
  • Soltero Cardiovascular Research Center
    Dallas, Texas 75226, United States
  • Orion Medical
    Houston, Texas 77034, United States
  • Inova Fairfax Hospital
    Falls Church, Virginia 22042, United States
  • Virginia Heart
    Falls Church, Virginia 22042, United States
  • Swedish Medical Center-Cardiovascular Research
    Seattle, Washington 98122, United States
  • Univ of Washington Medical Center
    Seattle, Washington 98195, United States
  • Novartis Investigative Site
    Caba, Buenos Aires C1119ACN, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1428DCO, Argentina
  • Novartis Investigative Site
    Auchenflower, Queensland 4066, Australia
  • Novartis Investigative Site
    Chemside, Queensland 4032, Australia
  • Novartis Investigative Site
    Milton, Queensland 4064, Australia
  • Novartis Investigative Site
    Leabrook, South Australia 5068, Australia
  • Novartis Investigative Site
    Turnhout, Antwerpen 2300, Belgium
  • Novartis Investigative Site
    Genk, Limburg 3600, Belgium
  • Novartis Investigative Site
    Hasselt, Limburg 3500, Belgium
  • Novartis Investigative Site
    Yvoir, Namur 5530, Belgium
  • Novartis Investigative Site
    Aalst, Oost Vlaanderen 9300, Belgium
  • Novartis Investigative Site
    Curitiba, Paraná 80040-050, Brazil
  • Novartis Investigative Site
    Porto Alegre, Rio Grande do Sul 90560-032, Brazil
  • Novartis Investigative Site
    São Paulo, 01409-902, Brazil
  • Novartis Investigative Site
    North York, Ontario M6B 3H7, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1Y 4W7, Canada
  • Novartis Investigative Site
    Montreal, Quebec H1T 1C8, Canada
  • Novartis Investigative Site
    Santiago, Santiago Metropolitan 8380465, Chile
  • Novartis Investigative Site
    Beijing, Beijing Municipality 100013, China
  • Novartis Investigative Site
    Nanjing, Jiangsu 211166, China
  • Novartis Investigative Site
    Beijing, 100050, China
  • Novartis Investigative Site
    Shanghai, 200080, China
  • Novartis Investigative Site
    Paris, 75013, France
  • Novartis Investigative Site
    Pessac, 33604, France
  • Novartis Investigative Site
    Poitiers, 86021, France
  • Novartis Investigative Site
    Toulouse, 31054, France
  • Novartis Investigative Site
    Budapest, 1083, Hungary
  • Novartis Investigative Site
    Szeged, 6725, Hungary
  • Novartis Investigative Site
    Bangalore, Karnataka 560069, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110017, India
  • Novartis Investigative Site
    New Delhi, National Capital Territory of Delhi 110060, India
  • Novartis Investigative Site
    Chennai, Tamil Nadu 600081, India
  • Novartis Investigative Site
    Coimbatore, Tamil Nadu 641009, India
  • Novartis Investigative Site
    Lucknow, Uttar Pradesh 226003, India
  • Novartis Investigative Site
    Dehradun, Uttarakhand 248001, India
  • Novartis Investigative Site
    New Delhi, 110025, India
  • Novartis Investigative Site
    Dublin, Ireland D03 VX82, Ireland
  • Novartis Investigative Site
    Galway, H91 YR71, Ireland
  • Novartis Investigative Site
    Milan, MI 20138, Italy
  • Novartis Investigative Site
    Milan, MI 20157, Italy
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Miyhazaki, Miyazaki 8802102, Japan
  • Novartis Investigative Site
    Urasoe, Okinawa 9012102, Japan
  • Novartis Investigative Site
    Izumisano, Osaka 5988577, Japan
  • Novartis Investigative Site
    Kyoto, 6078062, Japan
  • Novartis Investigative Site
    Bundang Gu, Gyeonggi-do 13620, South Korea
  • Novartis Investigative Site
    Goyang-si, Gyeonggi-do 10380, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Seoul, 07804, South Korea
  • Novartis Investigative Site
    A Coruña, 15006, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08041, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Madrid, 28040, Spain
  • Novartis Investigative Site
    Salamanca, 37007, Spain
  • Novartis Investigative Site
    Valencia, 46010, Spain
  • Novartis Investigative Site
    Geneva, 1211, Switzerland
  • Novartis Investigative Site
    Lugano, 6900, Switzerland
  • Novartis Investigative Site
    Newcastle upon Tyne, Tyne and Wear NE7 7DN, United Kingdom
  • Novartis Investigative Site
    Edinburgh, EH16 4SA, United Kingdom
08

References and documents

Publications

  • Revaiah PC, Serruys PW, Onuma Y, Andreini D, Budoff MJ, Sharif F, Chernofsky A, Vikarunnessa S, Wiethoff AJ, Yates D, Achouba A. Design and rationale of a randomized clinical trial assessing the effect of inclisiran on atherosclerotic plaque in individuals without previous cardiovascular event and without flow- limiting lesions identified in an in-hospital screening: The VICTORION-PLAQUE primary prevention trial. Am Heart J. 2026 Jan;291:199-212. doi: 10.1016/j.ahj.2025.08.001. Epub 2025 Aug 30. PubMed 40769373 ↗

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Oct 2026, 51 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Coronary Artery Disease, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 55. This study's planned 51 months is close to that.

Counting every sponsor, half of 61 studies reached it within 47 months; a quarter within 20 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2022
First posted
May 4, 2022
StartActual
Jul 8, 2022
Primary completionEst.
Oct 26, 2026
CompletionEst.
Oct 27, 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Study completion
Oct 26, 2026→Oct 27, 2026
Oct 26, 2026
Enrollment
609 (actual)→610 (estimated)
Oct 5, 2026
Show all 2 updates
  1. Oct 26, 2026
    Study completion Oct 26, 2026→Oct 27, 2026
    + 2 other changes: verification date and site details
  2. Oct 5, 2026
    Enrollment 609 (actual)→610 (estimated)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05360446
Responsible party
Sponsor
First posted
May 4, 2022
Start date
Jul 8, 2022
Primary completion
Oct 26, 2026 (estimated)
Completion
Oct 27, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inclisiran

Start the discussion